North Bay Neuro Science

Current Studies

Stages-Clinical-Trials

North Bay Neuroscience Institute is engaged in a number of clinical trials or studies. All of them are researching new medicines designed to offset the impact of Alzheimer’s Disease.

We engage in clinical trials at either Phase II and III stages. Presently all of our trials are those in Phase III.

Our current studies are:

CREAD: Crenezumab for Prodromal to Mild Alzheimer’s Disease

Status: Closed and ending

Description: This clinical trial will test the experimental drug crenezumab in people with early to mild Alzheimer’s disease. Investigators will assess the drug’s safety and efficacy and evaluate any changes in participants’ dementia rating and performance on neuropsychological tests

Learn more at: United States Department of Health & Human Services Clinical Trials Listing or the Cread Website

EMERGE: Aducanumab (BIIB037) for Early Alzheimer’s Disease

Status: Closed and ending

Description: This study will evaluate the efficacy of the experimental drug aducanumab (BIIB037), compared with a placebo, in slowing cognitive and functional impairment in people with early-stage Alzheimer’s disease. Participants will receive monthly infusions.

Learn more at: United States Department of Health & Human Services Clinical Trials Listing

GENERATION 1 & 2: CNP520 to Slow or Prevent Alzheimer’s

Status: Actively recruiting

Description: The Generation studies will test the safety and effects of the investigational drug CNP520 in cognitively normal older adults who are at risk of developing dementia based on their age, genetic Status:, and brain amyloid levels.

Learn more at: United States Department of Health & Human Services Clinical Trials Listing  or the Generation Website

GRADUATE 1: Gantenerumab for Prodromal to Mild Alzheimer’s Disease

Status: Closed and ending

Description: This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD.

Learn more at: United States Department of Health & Human Services Clinical Trials Listing  or the Alzheimer News Today Website

LLCF: LY3202626 for mild Alzheimer’s Disease

Status: Terminated (final stage)

Description: The main purpose of this study is to evaluate the safety and the effect on brain tau of the study drug LY3202626 in participants with mild Alzheimer’s disease (AD) dementia.

Learn more at: United States Department of Health & Human Services Clinical Trials Listing

Eisai: BAN2401-G000-301 for Early Alzheimer’s Disease

Status: Enrolling

Description:  A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease

Learn more at: United States National Library of Medicine, clinicaltrials.gov

© Northbay Neuroscience Institute